Molecular Staging and the Selection of Therapy for Non-Small Cell Lung Cancer

被引：2
作者：
D'Amico, Thomas A. [1 ]
机构：
[1] Duke Univ, Med Ctr, Div Thorac Surg, Durham, NC USA
来源：
SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY | 2005年 / 17卷 / 03期
关键词：
lung cancer; molecular biology; targeted therapy;
D O I：
10.1053/j.semtcvs.2005.06.011
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The stage-specific selection of therapy is the standard for patients with non-small cell lung cancer. Investigation of the molecular biology of lung cancer has provided pathways and targets that may be used to improve the efficacy of therapy and improve the survival for patients with lung cancer. © 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码：180 / 185
页数：6
相关论文
共 44 条
  • [1] Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer
    Altorki, NK
    Keresztes, RS
    Port, JL
    Libby, MD
    Korst, RJ
    Flieder, DB
    Ferrara, CA
    Yankelevitz, DF
    Subbaramaiah, K
    Pasmantier, MW
    Dannenberg, AJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) : 2645 - 2650
  • [2] Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: A novel approach for patient selection
    Brooks, KR
    To, K
    Joshi, MBM
    Conlon, DH
    Herndon, JE
    D'Amico, TA
    Harpole, DH
    [J]. ANNALS OF THORACIC SURGERY, 2003, 76 (01) : 187 - 193
  • [3] Protein profiles associated with survival in lung adenocarcinoma
    Chen, GA
    Gharib, TG
    Wang, H
    Huang, CC
    Kuick, R
    Thomas, DG
    Shedden, KA
    Misek, DE
    Taylor, JMG
    Giordano, TJ
    Kardia, SLR
    Iannettoni, MD
    Yee, J
    Hogg, PJ
    Orringer, MB
    Hanash, SM
    Beer, DG
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (23) : 13537 - 13542
  • [4] A biologic risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markers
    D'Amico, TA
    Massey, M
    Herndon, JE
    Moore, MB
    Harpole, DH
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1999, 117 (04) : 736 - 742
  • [5] Molecular biologic substaging of stage I lung cancer according to gender and histology
    D'Amico, TA
    Aloia, TA
    Moor, MBH
    Herndon, JE
    Brooks, KR
    Lau, CL
    Harpole, DH
    [J]. ANNALS OF THORACIC SURGERY, 2000, 69 (03) : 882 - 886
  • [6] Molecular staging of lung cancer: Real-time polymerase chain reaction estimation of lymph micrometastatic tumor cell burden on-small cell lung cancer - Preliminary results of Cancer and Leukemia Group B Trial 9761
    D'Cunha, J
    Corfits, AL
    Herndon, JE
    Kern, JA
    Kohman, LJ
    Patterson, GA
    Kratzke, RA
    Maddaus, MA
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2002, 123 (03) : 484 - 491
  • [7] DeVore R., 2000, P AN M AM SOC CLIN, p485a
  • [8] Novel targets for lung cancer therapy: Part II
    Dy, GK
    Adjei, AA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (13) : 3016 - 3028
  • [9] Fosslien E, 2000, ANN CLIN LAB SCI, V30, P3
  • [10] Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer
    Gatzemeier, U
    Groth, G
    Butts, C
    Van Zandwijk, N
    Shepherd, F
    Ardizzoni, A
    Barton, C
    Ghahramani, P
    Hirsh, V
    [J]. ANNALS OF ONCOLOGY, 2004, 15 (01) : 19 - 27
12345